Journal
Cancer chemotherapy and pharmacology
Publication Date
4-1-2022
Volume
89
Issue
4
First Page
499
Last Page
514
Document Type
Open Access Publication
DOI
10.1007/s00280-022-04414-6
Rights and Permissions
Felip, E., Moreno, V., Morgensztern, D. et al. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol 89, 499–514 (2022). https://doi.org/10.1007/s00280-022-04414-6 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Felip, Enriqueta; Morgensztern, Daniel; and et al., "First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers." Cancer chemotherapy and pharmacology. 89, 4. 499 - 514. (2022).
https://digitalcommons.wustl.edu/oa_4/799
Additional Links
Supplemental material is available for this article at publisher site.
